The use of bacteriophages in therapy has gained traction in recent years as a promising alternative to antibiotics due to the rise in antibiotic resistance. While the potential of bacteriophages in clinical practice is being explored, the need for standardized purification methods to ensure safety remains a significant concern. In a recent study, various purification techniques were evaluated to assess their efficacy in removing endotoxins from bacteriophage preparations. The study focused on three common purification methods: Triton X-100 exposure, CsCl density gradient ultracentrifugation, and Pierce™ High-Capacity Endotoxin Removal Resin spin columns, testing them on different bacteriophage morphotypes.
Bacteriophages, discovered in the early 20th century, are viruses that infect bacteria and are being considered as a viable alternative to antibiotics. However, ensuring their safety for therapeutic use is essential. Despite reports of bacteriophage therapy safety, adverse events have been noted, emphasizing the need for standardized purification methods. In this study, Triton X-100 purification demonstrated the highest efficacy in reducing endotoxin levels and immune responses, followed closely by CsCl density gradient ultracentrifugation, while purification with Pierce™ High-Capacity Endotoxin Removal Resin spin columns showed less effectiveness.
The study utilized three bacteriophage morphotypes—siphovirus, podovirus, and myovirus—to evaluate the purification methods’ impact on different virus types. The findings revealed that the morphology of the virus did not significantly affect the purification efficacy. Furthermore, the study introduced a novel human immune cell-based system for assessing endotoxin concentrations in bacteriophage preparations, providing a more comprehensive understanding of the purification process’s outcomes.
Bacteriophage preparations were subjected to Triton X-100 exposure, CsCl density gradient ultracentrifugation, and Pierce™ High-Capacity Endotoxin Removal Resin spin columns. The results indicated that Triton X-100 purification method not only effectively reduced endotoxin levels but also preserved a higher bacteriophage titre compared to the other methods. Additionally, CsCl ultracentrifugation showed comparable efficacy in endotoxin removal but with a slightly lower recovery rate of bacteriophages, while the Pierce™ resin columns were the least effective in removing endotoxins.
The study’s findings highlight the importance of selecting appropriate purification methods for bacteriophages to ensure their safety and efficacy in therapeutic applications. Despite concerns about the residual chemicals from purification methods, steps such as repeated washing with PBS were implemented to minimize any adverse effects. Overall, Triton X-100 purification emerged as a promising method for effectively removing endotoxins while maintaining bacteriophage viability, emphasizing the significance of standardized purification protocols in bacteriophage therapy.
Key Takeaways:
1. Evaluation of bacteriophage purification methods is crucial for ensuring safety and efficacy in therapeutic applications.
2. Triton X-100 exposure demonstrated the highest efficacy in removing endotoxins and preserving bacteriophage titre.
3. CsCl density gradient ultracentrifugation showed comparable efficacy in endotoxin removal but with a slightly lower recovery rate.
4. Pierce™ High-Capacity Endotoxin Removal Resin spin columns were the least effective in removing endotoxins, especially with repeated use.
5. The morphology of bacteriophages did not significantly impact the purification efficacy of the methods evaluated.
6. Novel immune cell-based systems can provide valuable insights into the purification process and its outcomes.
Tags: chromatography, regulatory, clinical trials
Read more on pmc.ncbi.nlm.nih.gov